Docket No. 529452000122

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on April 16, 2003.

Martina Placid

Martina Placid

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

David W. MORRIS and Eric K. ENGELHARD

Serial No.: 10/087,192

Filing Date: March 1, 2002

For: NOVEL COMPOSITIONS AND METHODS FOR CANCER

Examiner: To Be Assigned

Group Art Unit: 1642

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97 AND § 1.98

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

☐ With the application; accordingly, no fee or separate requirements are required.

☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.

☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.

- ☐ A fee is required. A check in the amount of is enclosed.
- ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.

☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.

- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of is enclosed.
- ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17 is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for

any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 529452000122. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: April 16, 2003

Respectfully submitted,

By: _____

Shantanu Basu
Registration No. 43,318

Morrison & Foerster LLP
755 Page Mill Road
Palo Alto, California 94304-1018
Telephone: (650) 813-5995
Facsimile: (650) 494-0792

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000122	Application Number 10/087,192
Applicant: David W. MORRIS and Eric K. ENGELHARD	
Filing Date March 1, 2002	Group Art Unit 1642
Mailing Date April 16, 2003	

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate
	1.	12/18/1979	4,179,337	Davis et al.			
	2.	11/17/1981	4,301,144	Iwashita et al.			
	3.	09/04/1984	4,469,863	Ts'o et al.			
	4.	01/29/1985	4,496,689	Mitra			
	5.	02/03/1987	4,640,835	Shimizu et al.			
	6.	06/02/1987	4,670,417	Iwasaki et al.			
	7.	12/13/1988	4,791,192	Nakagawa et al.			
	8.	03/28/1989	4,816,567	Cabilly et al.			
	9.	07/23/1991	5,034,506	Summerton et al.			
	10.	06/23/1992	5,124,246	Urdea et al.			
	11.	06/01/1993	5,216,141	Benner			
	12.	08/10/1993	5,235,033	Summerton et al.			
	13.	10/25/1994	5,359,100	Urdea et al.			
	14.	01/31/1995	5,386,023	Sanghvi et al.			
	15.	08/29/1995	5,445,934	Fodor et al.			
	16.	08/13/1996	5,545,730	Urdea et al.			
	17.	08/13/1996	5,545,806	Lonberg et al.			
	18.	08/13/1996	5,545,807	Surani et al.			
	19.	10/29/1996	5,569,825	Lonberg et al.			
	20.	11/05/1996	5,571,670	Urdea et al.			
	21.	12/03/1996	5,580,731	Chang et al.			
	22.	01/07/1997	5,591,584	Chang et al.			
	23.	01/14/1997	5,594,117	Urdea et al.			
	24.	01/14/1997	5,594,118	Urdea et al.			
	25.	01/28/1997	5,597,909	Urdea et al.			
	26.	02/11/1997	5,602,240	De Mesmaeker et al.			

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000122	Application Number 10/087,192
Applicant: David W. MORRIS and Eric K. ENGELHARD	
Filing Date March 1, 2002	Group Art Unit 1642
Mailing Date April 16, 2003	

	27.	04/29/1997	5,624,802	Urdea et al.			
	28.	04/29/1997	5,625,126	Lonberg et al.			
	29.	05/27/1997	5,633,425	Lonberg et al.			
	30.	06/03/1997	5,635,352	Urdea et al.			
	31.	06/10/1997	5,637,684	Cook et al.			
	32.	07/01/1997	5,644,048	Yau			
	33.	08/26/1997	5,661,016	Lonberg et al.			
	34.	10/28/1997	5,681,697	Urdea et al.			
	35.	10/28/1997	5,681,702	Collins et al.			
	36.	12/23/1997	5,700,637	Southern			
	37.	11/28/2000	6,153,441	Appelbaum et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES	Translation NO
	38.	09/11/1987	WO 87/05330	WIPO				
	39.	09/20/1990	WO 90/10448	WIPO				
	40.	04/18/1991	WO 91/04753	WIPO				
	41.	11/11/1993	WO 93/22443	WIPO				
	42.	09/21/1995	WO 95/25116	WIPO				
	43.	12/28/1995	WO 95/35505	WIPO				
	44.	07/31/1997	WO 97/27212	WIPO				
	45.	07/31/1997	WO 97/27213	WIPO				

OTHER DOCUMENTS *(including author, title, Date, Pertinent Pages, Etc.)*

Examiner Initials	Ref. No.	Title
	46.	Allen, J. D. and Berns, A. (1996). "Complementation Tagging of Cooperating Oncogenes in Knockout Mice," *Cancer Biology* 7:299-306.
	47.	Altschul, S. F. and Gish, W. (1996). "Local Alignment Statistics" *In* Methods in Enzymology Vol. 266, Academic Press, Inc., pp. 460-480.
	48.	Altschul, S. F. et al. (1990). "Basic Local Alignment Search Tool," *J. Mol. Biol.* 215:403-410.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000122	Application Number 10/087,192
Applicant: David W. MORRIS and Eric K. ENGELHARD	
Filing Date March 1, 2002	Group Art Unit 1642
Mailing Date April 16, 2003	

✓	49.	Aplin, J. D. and Wriston, Jr., J. C. (1981). "Preparation, Properties, and Applications of Carbohydrate Conjugates of Proteins and Lipids," *CRC Crit. Rev. Biochem.* pp. 259-306.
✓	50.	Arenberg, D. A. et al. (2001). "The Murine CC Chemokine, 6C-Kine, Inhibits Tumor Growth and Angiogenesis in a Human Lung Cancer SCID Mouse Model," *Cancer Immunol. Immunother.* 49:587-592.
✓	51.	Ausubel, F. M. et al., eds. (1992). Short Protocols in Molecular Biology. Greene Publishing Associates and John Wiley & Sons, pp. iii-xviii (Table of Contents Only).
✓	52.	Bai, J. et al. (1999). "Sequence Comparison of JSRV with Endogenous Proviruses: Envelope Genotypes and a Novel ORF With Similarity to a G-Protein-Coupled Receptor," *Virology* 258:333-343.
✓	53.	Beaucage, S. L. and Iyer, R. P. (1993). "The Functionalization of Oligonucleotides Via Phosphoramidite Derivatives," *Tetrahedron* 49(10):1925-1963.
✓	54.	Boener, P. et al. (1991). "Production of Antigen-Specific Human Monoclonal Antibodies from in Vitro-Primed Human Splenocytes," *J. Immunol.* 147(1):86-95.
✓	55.	Bolli. M. et al. (1994). "α-Bicyclo-DNA: Synthesis, Characterization, and Pairing Properties of α-DNA-Analogues with Restricted Conformational Flexibility in the Sugar-Phosphate Backbone," Chapter 7 *In* Carbohydrate Modifications in Antisense Research. ACS Symposium Series 580, Shanghvi, Y. S and Cook, P. D, eds, American Chemical Society, Washington, pp. 100-117.
✓	56.	Brill, W. et al. (1989). "Synthesis of Oligodeoxynucleoside Phosphoridithioates via Thioamidites," *J. Am Chem soc.* 111:2321-2322.
✓	57.	Brower, V. (1998). "Naked DNA Vaccines Come of Age," *Nature Biotechnology* 16:1304-1305.
✓	58.	Carlsson, C. et al. (1996). "Screening for Genetic Mutations," *Nature* 380:207 (1 page total).
✓	59.	Cole, S.P.C., et al. (1985). "The EBV-Hybridoma Technique and Its Application to Human Lung Cancer," *In* Monoclonal Antibodies and Cancer Therapy, Reisfeld, R. A. and Sell, S., ed., Alan R. Liss, New York, p. 77-96 (Includes Table of Contents).
✓	60.	Creighton, T. E., ed. (1983). "Posttranslational Covalent Modifications of Polypeptide Chains," Chapter 2.4 *In* Proteins: Structure and Molecular Properties. W. H. Freeman & Co., San Francisco pp. 78-86 (Includes Table of Contents).
✓	61.	David, G. S. and Reisfeld, R. A. (1974). "Protein Iodination with Solid State Lactoperoxidase," *Biochemistry* 13(5):1014-1021.
✓	62.	De Mesmaeker, A. et al. (1994). "Comparison of Rigid and Flexible Backbones in Antisense Oligonucleotides," *Bioorganic & Medicinal Chem. Lett.* 4(3):395-398.
✓	63.	De Mesmaeker, A. et al. (1994). "Novel Backbone Replacements for Oligonucleotides," Chapter 2 *In* Carbohydrate Modifications in Antisense Research, ACS Symposium Series 580.. Shanghvi, Y. S and Cook, P. D, eds, American Chemical Society, Washington, pp. 24-39.
✓	64.	Dempcy, R. O. et al. (1995). "Synthesis of a Thymidyl Pentamer of Deoxyribonucleic Guanidine and Binding Studies with DNA Homopolynucleotides," *Proc. Natl Acad. Sci. USA* 92:6097-6101.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000122	Application Number 10/087,192
Applicant: David W. MORRIS and Eric K. ENGELHARD	
Filing Date March 1, 2002	Group Art Unit 1642
Mailing Date April 16, 2003	

	65.	Desbois, C. et al. (1996). "Exclusion of *Int*-6 from PML Nuclear Bodies by Binding to the HTLV-1 Tax Oncoprotein," *Science* 273:951-953.
	66.	Devereux et al. (1984). "A Comprehensive Set of Sequence Analysis Programs for the VAX," *Nuc. Acid. Res.* 12(1):387-395.
	67.	Doudney, K. et al. (2001). "Comparative Physical and Transcript Maps of ~ 1 Mb around *looptail*, a Gene for Severe Neural Tube Defects on Distal Mouse Chromosome 1 and Human Chromosome 1q22-q23," *Genomics* 72(2):180-192.
	68.	Eckstein. F., ed. (1991). Oligonucleotides and Analogues: A Practical Approach, Oxford University Press, vii-xvii. (Table of Contents Only).
	69.	Edge, A. S. B. et al. (1981). "Deglycosylation of Glycoproteins by Trifluoromerathneusulfonic Acid," *Anal. Biochem.* 118:131-137.
	70.	Egholm, M. (1993). "PNA Hybridizes to Complementary Oligonucleotides Obeying the Watson-Crick Hydrogenbonding," *Nature* 365:566-568.
	71.	Elgholm, M. et al. (1992). "Peptide Nucleic Acids (PNA). Oligonucleotide Analogues with an Achiral Peptide Backbone," *J. Am. Chem. Soc.* 114:1895-1897.
	72.	Erny, K. M. et al. (1996). "Involvement of the *Tpl-2/cot* Oncogene in MMTV Turmorigenesis," *Oncogene* 13:2015-2020.
	73.	Evan, G. I. et al. (1985). "Isolation of Monoclonal Antibodies Specific for Human c-myc Proto-Oncogene Product," *Biology* 5(12):3610-3616.
	74.	Fan, L. et al. (2000). "Cutting Edge: Ectopic Expression of the Chemokine TCA4/SLC is Sufficient to Trigger Lymphoid Neogenesis," *J. Immunol.* 164(8):3955-3959.
	75.	Feng, D. F. & Doolittle, R. F. (1987). "Progressive Sequence Alignment as a Prerequisite to Correct Phylogenetic Trees," *J. Mol. Evol.* 25:351-360.
	76.	Field, J. et al. (1988). "Purification of a RAS-Responsive Adenylyl Cyclase Complex from Saccharomyces Cerevisiae by Use of a Epitope Addition Method," *Mol Cell. Biol.* 8(5):2159-2165.
	77.	Fishwild, D. M.et al. (1996). "High-Avidity Human IgGk Monoclonal Antibodies from a Novel Strain of Minilocus Transgenic Mice," *Nature Biotechnology* 14:845-851.
	78.	Gallahan, D. and Callahan, R. (1987). "Mammary Tumorigenesis in Feral Mice: Identification of a New *int* Locus in Mouse Mammary Tumor Virus (Czech II)-Induced Mammary Tumors," *J. Virol.* 61(1):66-74.
	79.	Gao, X. and Jeffs, W. P. (1994). "Unusual Conformation of a 3'-thioformacetal Linkage in a DNA Duplex," *J. Biomolecular NMR* 4:17-34.
	80.	Germer, S. et al. (2000). "High-Throughput SNP Allele-Frequency Determination in Pooled DNA Samples by Kinetic PCR," *Genome Res.* 10:258-266.
	81.	Goding, J. W. (1986). "Production of Monoclonal Antibodies," Chapter 3 *In* Monoclonal Antibodies: Principles and Practice, Academic Press, Inc., 2nd edition, pp. 59-103.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000122	Application Number 10/087,192
Applicant: David W. MORRIS and Eric K. ENGELHARD	
Filing Date March 1, 2002	Group Art Unit 1642
Mailing Date April 16, 2003	

	82.	Hansen, G. M. et al. (2000). "Genetic Profile of Insertion Mutations in Mouse Leukemias and Lymphomas," *Genome Res.* 10(2):237-243.
	83.	Heid, C. A et al. (1996). "Real Time Quantitative PCR," *Genome Research* 6:986-994.
	84.	Herdewjn, P. et al. (1994). "Hexopyranosyl-Like Oligonucleotides," Chapter 6 *In* Carbohydrate Modifications in Antisense Research. Shanghvi, Y. S and Cook, P. D, eds, ACS Symposium Series 580, American Chemical Society, Washington, pp. 80-99.
	85.	Higgins, D. G. and Sharp, P. M. (1989). "Fast and Sensitive Multiple Sequence Alignments on a Microcomputer," *CABIOS Communications* 5(2):151-153.
	86.	Hoogenboom, H. R. and Winter, G. (1991). "By-Passing Immunisation Human Antibodies from Synthetic Repertoires of Germline V_H Gene Segments Rearranged in Vitro," *J. Mol. Biol.* 227:381-388.
	87.	Hopp, T. P. et al. (1988). "A Short Polypeptide Marker Sequence Useful for Recombinant Protein Identification and Purification," *Biotechnology* 6:1204-1210.
	88.	Horn, T. et al. (1996). "Oligonucleotides with Alternating Anionic and Cationic Phosphoramidate Linkages: Synthesis and Hybridization of Stereo-Uniform Isomers," *Tetrahedron Letters* 37(6):743-746.
	89.	Hwang, H. C. et al. (2002). "Identification of Oncognes Collaborating with $p27^{Kip1}$ Loss by Insertional Mutagenesis and High-Throughput Insertion Site Analysis," *Proc. Natl Acad. Sci. USA* 99(17):11293-11298 (Includes supporting information).
	90.	Jenkins, G. N. and Turner, N. J. (1995). "The Biosynthesis of Carbocyclic Nucleosides," *Chem. Soc. Rev.* pp. 169-176.
	91.	Jones, P. T. et al. (1986). "Replacing the Complementarity-Determining Regions in a Human Antibody with Those from a Mouse," *Nature* 321:522-525.
	92.	Jonkers, J. and Berns, A. (1996). "Retroviral Insertional Mutagenesis as a Strategy to Identify Cancer Genes," *Biochim. Biophys. Acta* 1287:29-57.
	93.	Joosten, M. et al. (2000). "Phenotyping of Evi 1, Evi 11/Cb2, and Evi 12 Transformed Leukemias Isolated from a Novel Panel of Cas-Br-M Murine Leukemia Virus-Infected Mice," *J. Virology* 268:308-318.
	94.	Jung, M. P. et al. (1994). "Hybridization of alternating Cationic/Anionic Oligonucleotides to RNA Segments," *Nucleosides & Nucleotides* 13(6&7):1597-1605.
	95.	Karlin, S. and Altschul, S.F. (1993). "Applications and Statistics for Multiple High-Scoring Segments in Molecular Sequences," *Proc. Natl Acad. Sci. USA* 90:5873-5877.
	96.	Köhler, G. and Milstein, C. (1975). "Continuous Cultures of Fused Cells Secreting Antibody of Predefined Specificity," *Nature* 256:495-497.
	97.	Kohno, T. et al. (2000). "Identification of Genes Associated with the Progression of Adult T-Cell Leukemia (ATL)," *Jpn. J. Cancer Res.* 91:1103-1110.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 529452000122	Application Number 10/087,192
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Applicant: David W. MORRIS and Eric K. ENGELHARD	
	Filing Date March 1, 2002	Group Art Unit 1642
	Mailing Date April 16, 2003	

	98.	Lee, F. S. et al. (1995). "Insertional Mutagenesis Identifies a Member of the *Wnt* Gene Family as a Candidate Oncogene in the Mammary Eptithelium of *int-2/Fgf-3* Transgenic Mice," *Proc. Natl. Acad. Sci. USA* 92:2268-2272.
	99.	Lee, S. Wong et al. (1999). "Cloning of Mouse Sepiapterin Reductase Gene and Characterization of its Promoter Region," *Biochimica and Biophysica Acta* 1445(1):165-171.
	100.	Letsinger, R. L. et al. (1986). "Effects of Pendant Groups at Phosphorus on Binding Properties of d-ApA Analogues," *Nucl. Acids. Res* 14(8):3487-3499.
	101.	Letsinger, R. L. et al. (1988). "Cationic Oligonucleotides," *J. Am. Chem. Soc.* 110:4470-4471.
	102.	Letsinger, R.L. and Mungall, W. S. (1970). "Phosphoramidate Analogs of Oligonucleotides," *J. Org. Chem* 35(11):3800-3803.
	103.	Li, J. et al. (1999). "Leukaemia Disease Genes: Large-Scale Cloning and Pathway Predictions," *Nature Genetics* 23:348-353.
	104.	Lockhart, D. J. et al. (1996). "Expression Monitoring by Hybridization High-Density Oligonucleotide Arrays," *Nature Biotechnology*, 14:1675-1680.
	105.	Lonberg, N. and Huszar, D. (1995). "Human Antibodies from Transgenic Mice," *Intern. Rev. Immunol.* 13:65-93.
	106.	Longberg, N. et al. (1994). "Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications," *Nature* 368:856-859.
	107.	Lund, A. H. et al. (2002). "Genome-Wide Retroviral Insertional Tagging of Genes Involved in Cancer in Cdkn2a-Deficient Mice," *Nature Genetics Advance online Publication* pp. 1-6.
	108.	Lutz-Freyermuth, C. et al. (1990). "Quantitative Determination That One of Two Potential RNA-Binding Domains of the A Protein Component of the U1 Small Nuclear Ribonucleoprotein Complex Binds with High Affinity to Stem-Loop II of U1 RNA," *Proc. Natl Acad. Sci. USA* 87:6393-6397.
	109.	MacArthur, C. A. et al. (1995). "*Fgf-8*, Activated by Proviral Insertion, Cooperates with the *Wnt-1* Transgene in Murine Mammary Tumorigenesis," *J. Virol.* 69(4):2501-2507.
	110.	Maddry, J. A. et al. (1994). "Synthesis of Nonionic Olgonucleotide Analogues," Chapter 3 *In* Carbohydrate Modifications in Antisense Research. Shanghvi, Y. S and Cook, P. D, eds, ACS Symposium Series 580 American Chemical Society, Washington, pp. 40-51.
	111.	Mag, M. et al. (1991). "Synthesis and Selective Cleavage of an Oligodeoynucleotide Containing a Bridged Internucleotide 5'-Phosphorotiate Linkage," *Nucleic Acids Res.* 19(7):1437-1441.
	112.	Marchetti, A. et al. (1995). "*Int-6*, a Highly Conserved, Widely Expressed Gene, is Mutated by Mouse Mammary Tumor Virus in Mammary Preneoplasia," *J. Virol.* 69(3):1932-1938.
	113.	Marks, J. D. et al. (1991). "By-Passing Immunization, Human Antibodies from V-Gene Libraries Displayed on Phage," *J. Mol. Biol.* 222:581-597.
	114.	Marks, J. D. et al. (1992). "By-Passing Immunization: Building High Affinity Human Antibodies by Chain Shuffling," *Bio/Technology* 10:779-783.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 529452000122	Application Number 10/087,192
Applicant: David W. MORRIS and Eric K. ENGELHARD	
Filing Date March 1, 2002	Group Art Unit 1642
Mailing Date April 16, 2003	

	115.	Martin, G. A. et al. (1992). "GAP Domains Responsible for Ras p21-Dependent Inhibition of Muscarinic Atrial K+ Channel Currents," *Science* 255:192-194.
	116.	Meier, C. et al. (1992). "Peptide Nucleic Acids (PNAs) -- Unusual Properties of Nonionic Oligonucleotide Analogues," *Angew Chem. Int. Ed. Engl.* 31(8):1008-1010.
	117.	Mikkers ,H. et al. (2002). "High-Throughput Retroviral Tagging to Identify Components of Specific Signaling Pathways in Cancer," *Nature Genetics Advance Online Publication*, pp. 1-7.
	118.	Moore, A. S. (2001). "The Role of Chemoattraction in Cancer Metastases," *BioEssays* 23(8):674-676.
	119.	Morris, D. W. et al. (1986). "Transfer, by Selective Breeding, of the Pathogenic *Mtv-2* Endogenous Provirus from the GR strain to a Wild Mouse Line Free of Endogenous and Exogenous Mouse Mammary Tumor Virus," *J. Virol.* 58(2):247-252.
	120.	Morris, D. W. et al. (1990). "Insertion Mutation of the *Int-1* and *Int-2* Loci by Mouse Mammary Tumor Virus in Premalignant and Malignant Neoplasms from the GR Mouse Strain," *J. Virol.* 64(4):1794-1802.
	121.	Morrison, S. L. (1994). "Success in Specification," *Nature* 368:812-813.
	122.	Müller, A. et al. (2001). "Involvement of Chemokine Receptors in Breast Cancer Metastasis," *Nature* 410:50-56.
	123.	Needleman, S. B. and Wunsch, C. D. (1970). "A General Method Applicable to the Search for Similiarities in the Amino Acid Sequence of Two Proteins," *J. Mol. Biol.* 48:443-453.
	124.	Neuberger, M. (1996). "Generating High-Avidity Human Mabs in Mice," *Nature Biotechnology* 14:826 (1 page total).
	125.	Nusse, R. and Varmus, H. E. (1982). "Many Tumors Induced by the Mouse Mammary Tumor Virus Contain a Provirus Integrated in the Same Region of the Host Genome," *Cell* 31:99-109.
	126.	Nygren, H. (1982). "Conjugation of Horseradish Peroxidase to Fab Fragments with Different Homobifunctional and Heterobifunctional Cross-Linking Reagents," *J. Histochem. and Cytochem.* 30(5):407-412.
	127.	Paborsky, L. R. et al. (1990). "Mammalian Cell Transient Expression of Tissue Factor for the Production of Antigen," *Protein Engineering* 3(6):547-553.
	128.	Pain, D. and Surolia, A. (1981). "Preparation of Protein A-Peroxidase Monoconjugate Using A Heterobifunctional Reagent, and its Use in Enzyme Immunoassays," *J. Immunol. Meth.* 40:219-230.
	129.	Palmarini, M. et al. (1999). "Jaagsiekte Sheep Retrovirus is Necessary and Sufficient to Induce a Contagious Lung Cancer in Sheep," *J. Virol.* 73(8):6964-6972.
	130.	Pauwels, R. et al. (1986). "Biological Activity of New 2-5A Analogues," *Chemica Scripta* 26:141-145.
	131.	Pearson, W. R. and Lipman, D. J. (1988). "Improved Tools for Biological Sequence Comparison," 85:2444-2448.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 529452000122	Application Number 10/087,192
INFORMATION DISCLOSURE CITATION IN AN APPLICATION (Use several sheets if necessary)	Applicant: David W. MORRIS and Eric K. ENGELHARD	
	Filing Date March 1, 2002	Group Art Unit 1642
	Mailing Date April 16, 2003	

		Peters, G. et al. (1983). "Tumorigenesis by Mouse Mammary Turmor Virus: Evidence for a Common Region for Provirus Integration in Mammary Tumors," *Cell* 33:369-377.
	133.	Peters, G. et al. (1989). "The Mouse Homolog of the *Hst/k-FGF* Gene is Adjacent to *int-2* and is Activated by Proviral Insertion in Some Virally Induced Mammary Tumors," *Proc. Natl. Acad. Sci. USA* 86:5678-5682.
	134.	Pierce (1994). "Cross-Linking," *Pierce Catalog and Handbook* pp. 155-200.
	135.	Presta, L. G. (1992). "Antibody Engineering", *Current Opinion in Structural Biology* 2:593-596.
	136.	Rawls, R. L. (1997). "Optimistic About Antisense," *C & E News* pp. 35-40.
	137.	Riechmann, L. et al. (1988). "Reshaping Human Antibodies for Therapy," *Nature* 332:323-327.
	138.	Roelink, H. et al. (1990). "*Wnt-3*, a Gene Activated by Proviral Insertion in Mouse Mammary Tumors is Homologous to *int-1/Wnt-1* and is Normally Expressed in Mouse Embryos and Adult Brain," *Proc. Natl. Acad. Sci USA* 87:4519-4523.
	139.	Sambrook, J. et al., eds. (1989). Molecular Cloning, a Laboratory Manual, Second Edition. Cold Spring Harbor Laboraroty Press. pp.xi-xxxviii. (Table of Contents Only).
	140.	Scopes, R. K.,ed. (1982). Protein Purification: Principles and Practice. Springer-Verlag, New York, Heidelberg, Berlin, pp. xi-xiii.
	141.	Shiramizu, B. et al. (1994). "Identification of a Common Clonal Human Immunodeficiency Virus Integration Site in Human Immunodeficiency Virus-Associated Lymphomas," *Cancer Res.* 54:2069-2072.
	142.	Smith, T. F. and Waterman, M. S. (1981). "Comparison of Biosequences," *Adv. Appl. Math.* 2:482-489.
	143.	Sojar, H. T. and Bahl, O. P. (1987). "A Chemical Method for the Deglycosylation of Proteins," *Archives of Biochemistry and Biophysics* 259(1):52-57.
	144.	Sorensen, A. B. et al. (1993). "Amplification and Sequence Analysis of DNA Flanking Integrated Proviruses by a Simple Two-Step Polymerase Chain Reaction Method," *Journal of Virology* 67(12):7118-7124.
	145.	Sorensen, A. B. et al. (1993). "Sequence Tags for Provirus Integration Sites in DNAs of Tumors Induced by the Murine Retrovirus SL3-3," *Journal of Virology* 70(6):4063-4070.
	146.	Sorensen, A. B. et al. (2000). "Sintl, a Common Integration Site in SL3-3-Induced T-Cell Lymphomas, Harbors a Putative Proto-Oncogene with Homology to the Septin Gene Family," *J. Virology* 74(5):2161-2168.
	147.	Sprinzl, M. et al. (1977). "Enzymatic Incorporation of ATP and CTP Analogues Into the 3' End of tRNA," *Eur. J. Biochem* 81:579-589.
	148.	Stein, C. A. and Cohen, J. S. (1988). "Oligodeoxynucleotides as Inhibitors of Gene Expression: A Review," *Cancer Res.* 48:2659-2668.
	149.	Sternsdorf, T. et al. (1997). "Nuclear Dots: Actors on Many Stages," *Immunobiology* 198:307-331.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449	Docket Number 529452000122	Application Number 10/087,192
INFORMATION DISCLOSURE CITATION IN AN APPLICATION *(Use several sheets if necessary)*	Applicant: David W. MORRIS and Eric K. ENGELHARD	
	Filing Date March 1, 2002	Group Art Unit 1642
	Mailing Date April 16, 2003	

	150.	Suzuki, T. et al. (2002). "New Genes Involved in Cancer Identified by Retroviral Tagging," *Nature Genetics Advance Online Publication* pp. 1-9.
	151.	Suzuki, T. et al. (2002). "Web Note A: CIS Definition, Retroviral Tagging in the Post-Genome Era Identifies New Genes Involved in Cancer". (1 page total).
	152.	Thotakura, N. R. and Bahl, O. P. (1987). "Enzymathic Deglycosylation of Glycoproteins," *In* Methods in Enzymology Academic Press, Inc., Vol. 138. pp. 350-359.
	153.	Tijssen (1993). "Overview of Principles of Hybridization and the strategy of nucleic acid assays," Chapter 2 *In* Laboratory Techniques in Biochemistry and Molecular Biology, Hybridization with Nucleic Acid Probes, Van der Vliet, P. C., ed. Elsevier, Amsterdam, London, New York, and Tokyo, Volume 24 pp. 20-78.
	154.	Van der Krol, A. R et al. (1988). "Modulation of Eukaryotic Gene Expression by Complementary RNA or DNA Sequences," *Biotechniques* 6(10):958-976.
	155.	Varmus, H. E. (1983). "Using Retroviruses as Insertional Mutagens to Identify Cellular Oncogenes," *In* Oncogenes and Retroviruses: Evaluation of Basic Findings and Clinical Potential. Alan R. Liss, Inc., New York. pp. 23-35.
	156.	Vaughn, J. et al. (2000). "Genomic Structure and Expression of Human *KCNJ9* (Kir3.3/GIRK3)," *Biochem. Biophys. Res. Commun.* 274(2):302-309.
	157.	Verhoeyen, M. et al. (1988). "Reshaping Human Antibodies: Grafting an Antilysozyme Activity," *Science* 239:1534-1536.
	158.	von Kiedrowski, G. et al. (1991). "Parabolic Growth of a Self-Replicating Hexdeoxynucleotide Bearing a 3'-5'-Phosphoamidate Linkage," *Angew. Chem. Int. Ed. Engl* 30(4):423-426.
	159.	Washington University. (2002). "Washington University BLAST Archives" located at http://blast.wustl visited on December 15, 2002.
	160.	Wolford, J. K. (2001). "Analysis of Linkage Disequilibrium Between Polymorphisms in the *KCNJ9* Gene with Type 2 Diabetes Mellitus in Pima Indians," *Mol. Genet. Metab* 73(1):97-103.
	161.	Zhang, W-X and Yang, S. Y. (2000). "Cloning and Characterization of a New Member of the T-Box Gene Family," *Genomics* 70(1):41-48.
	162.	Zlokarnik, G. et al. (1998). "Quantitation of Transcription and Clonal Selection of Single Living Cells with β-Lactamase as Reporter," *Science* 279:84-88.

EXAMINER:	DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.